| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Medical Research Council Toxicology Unit, University of Leicester, Leicester, United Kingdom; and 2 Istituto Pasteur, Fondazione Cenci-Bolognetti, Dipartimento di Studi Farmaceutici, Universita degli Studi di Roma "La Sapienza," Rome, Italy
Requests for reprints: Gerald M. Cohen, Medical Research Council Toxicology Unit, Hodgkin Building, University of Leicester, P.O. Box 138, Lancaster Road, Leicester LE1 9HN, United Kingdom. Phone: 44-116-2525601; Fax: 44-116-2525616; E-mail: gmc2{at}le.ac.uk.
From work done largely on derived cell lines, it has been suggested that tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) might be a therapeutic target for many forms of malignancy. However, use of primary tumor cells, including chronic lymphocytic leukemic (CLL) cells, has shown inherent resistance to TRAIL. Although the molecular basis for this resistance remains unknown, treatment with histone deacetylase inhibitors (HDACi) often sensitizes resistant cells to TRAIL-induced apoptosis. We used structurally diverse HDACi to ascertain which HDAC needs to be inhibited for the sensitization. Inhibition of HDAC class I but not class II is required for sensitization to TRAIL-induced apoptosis of CLL cells and various cell lines. Using different HDACi together with small interfering RNA for HDAC1, HDAC2, HDAC3, and HDAC6, we report that inhibition of HDAC1 and HDAC2 but not HDAC3, HDAC6, and HDAC8 are primarily responsible for sensitization to TRAIL-induced apoptosis. Based on these data and our previous studies, we propose that a clinical trial in CLL is warranted using a combination of a selective HDACi that inhibits HDAC1 and/or HDAC2 together with a form of TRAIL that signals through TRAIL receptor 1. (Cancer Res 2006; 66(13): 6785-92)
This article has been cited by other articles:
|
|
 |
|
  Z. Liu, A. Mai, and J. Sun Lysine Acetylation Regulates Bruton's Tyrosine Kinase in B Cell Activation J. Immunol., January 1, 2010; 184(1): 244 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Wood, S. Dalili, C. D. Simpson, M. A. Sukhai, R. Hurren, K. Anyiwe, X. Mao, F. Suarez Saiz, M. Gronda, Y. Eberhard, et al. Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands Mol. Cancer Ther., January 1, 2010; 9(1): 246 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Arts, P. King, A. Marien, W. Floren, A. Belien, L. Janssen, I. Pilatte, B. Roux, L. Decrane, R. Gilissen, et al. JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity Clin. Cancer Res., November 15, 2009; 15(22): 6841 - 6851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Inoue, N. Harper, R. Walewska, M. J.S. Dyer, and G. M. Cohen Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis Mol. Cancer Ther., November 1, 2009; 8(11): 3088 - 3097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ellis, P. W. Atadja, and R. W. Johnstone Epigenetics in cancer: Targeting chromatin modifications Mol. Cancer Ther., June 1, 2009; 8(6): 1409 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Haberland, A. Johnson, M. H. Mokalled, R. L. Montgomery, and E. N. Olson Genetic dissection of histone deacetylase requirement in tumor cells PNAS, May 12, 2009; 106(19): 7751 - 7755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Duong, C. Bret, L. Altucci, A. Mai, C. Duraffourd, J. Loubersac, P.-O. Harmand, S. Bonnet, S. Valente, T. Maudelonde, et al. Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells Mol. Cancer Res., December 1, 2008; 6(12): 1908 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ishdorj, B. A. Graham, X. Hu, J. Chen, J. B. Johnston, X. Fang, and S. B. Gibson Lysophosphatidic Acid Protects Cancer Cells from Histone Deacetylase (HDAC) Inhibitor-induced Apoptosis through Activation of HDAC J. Biol. Chem., June 13, 2008; 283(24): 16818 - 16829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Su, L. Altucci, and Q. You Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors Mol. Cancer Ther., May 1, 2008; 7(5): 1007 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-T. Liu, S. G. Agrawal, J. G. Gribben, H. Ye, M.-Q. Du, A. C. Newland, and L. Jia Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL Blood, March 1, 2008; 111(5): 2797 - 2805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J.S. Dyer, M. MacFarlane, and G. M. Cohen Barriers to Effective TRAIL-Targeted Therapy of Malignancy J. Clin. Oncol., October 1, 2007; 25(28): 4505 - 4506. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. West, D. M. Lucas, M. E. Davis, M. D. De Lay, A. J. Johnson, S. E. Guster, M. A. Freitas, M. R. Parthun, D. Wang, S. K. Kulp, et al. The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 2807 - 2807. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
